Searching the Resource Information Network

Our searching services are busy right now. Please try again later

  • Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes

A role for cytosolic fumarate hydratase in urea cycle metabolism and renal neoplasia.

Julie Adam | Ming Yang | Christina Bauerschmidt | Mitsuhiro Kitagawa | Linda O'Flaherty | Pratheesh Maheswaran | Gizem Özkan | Natasha Sahgal | Dilair Baban | Keiko Kato | Kaori Saito | Keiko Iino | Kaori Igarashi | Michael Stratford | Christopher Pugh | Daniel A Tennant | Christian Ludwig | Benjamin Davies | Peter J Ratcliffe | Mona El-Bahrawy | Houman Ashrafian | Tomoyoshi Soga | Patrick J Pollard
Cell reports | 2013

The identification of mutated metabolic enzymes in hereditary cancer syndromes has established a direct link between metabolic dysregulation and cancer. Mutations in the Krebs cycle enzyme, fumarate hydratase (FH), predispose affected individuals to leiomyomas, renal cysts, and cancers, though the respective pathogenic roles of mitochondrial and cytosolic FH isoforms remain undefined. On the basis of comprehensive metabolomic analyses, we demonstrate that FH1-deficient cells and tissues exhibit defects in the urea cycle/arginine metabolism. Remarkably, transgenic re-expression of cytosolic FH ameliorated both renal cyst development and urea cycle defects associated with renal-specific FH1 deletion in mice. Furthermore, acute arginine depletion significantly reduced the viability of FH1-deficient cells in comparison to controls. Our findings highlight the importance of extramitochondrial metabolic pathways in FH-associated oncogenesis and the urea cycle/arginine metabolism as a potential therapeutic target.

Pubmed ID: 23643539

Research resources used in this publication

None found

Antibodies used in this publication

None found

Associated grants

  • Agency: Cancer Research UK, United Kingdom
    Id: 13349
  • Agency: Wellcome Trust, United Kingdom
    Id: WT091112MA
  • Agency: European Research Council, International
    Id: 310837
  • Agency: Cancer Research UK, United Kingdom
    Id: A12027
  • Agency: Wellcome Trust, United Kingdom
    Id: 090532
  • Agency: Wellcome Trust, United Kingdom
    Id: 090532/Z/09/Z
  • Agency: Cancer Research UK, United Kingdom
    Id: A13349
  • Agency: Cancer Research UK, United Kingdom
    Id: A14607

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


GraphPad (tool)

RRID:SCR_000306

A commercial graphing software company that offers scientific software for statistical analyses, curve fitting and data analysis. It offers four programs: Prism, InStat, StatMate and QuickCalcs.

View all literature mentions

MP Biomedicals (tool)

RRID:SCR_013308

An Antibody supplier

View all literature mentions

Wako (tool)

RRID:SCR_013651

An Antibody supplier

View all literature mentions

C57BL/6J (tool)

RRID:IMSR_JAX:000664

Mus musculus with name C57BL/6J from IMSR.

View all literature mentions